Back to News
Market Impact: 0.35
Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany FundamentalsProduct Launches
Cytokinetics reported Q3 2026 total revenue of $47.6 million, compared with $1.9 million in Q3 2025. MYQORZO (aficamten) contributed $44.5 million in net product revenue for the quarter.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
CYTK0.75
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook